The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both “atypical” myeloproliferative disorders and myelodysplastic syndromes
Top Cited Papers
Open Access
- 15 August 2005
- journal article
- Published by American Society of Hematology in Blood
- Vol. 106 (4) , 1207-1209
- https://doi.org/10.1182/blood-2005-03-1183
Abstract
A somatic mutation in the JH2 autoinhibitory domain of the Janus kinase 2 (JAK2) tyrosine kinase was recently described in polycythemia vera, essentiKeywords
This publication has 25 references indexed in Scilit:
- Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisPublished by Elsevier ,2005
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersNew England Journal of Medicine, 2005
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005
- AMN107: Tightening the grip of imatinibCancer Cell, 2005
- Acquired α-thalassemia in association with myelodysplastic syndrome and other hematologic malignanciesBlood, 2005
- WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literatureLeukemia, 2004
- FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophiliaBlood, 2004
- Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor BetaNew England Journal of Medicine, 2002
- Chronic myeloid disorders: Classification and treatment overviewSeminars in Hematology, 2001
- Proposals for the classification of the myelodysplastic syndromesBritish Journal of Haematology, 1982